Muhammad Shoaib

Mr. Muhammad Shoaib

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2019 in Cancers
Verified
Journal Article
Open access
PDF file
TYTsukasa Yagi
Tsukasa Yagi
MSMuhammad Shoaib
Muhammad Shoaib
CKCyrus Kuschner
Cyrus Kuschner
MNMITSUAKI NISHIKIMI
MITSUAKI NISHIKIMI
LBLance Becker
Lance Becker
JKJunhwan Kim
Junhwan Kim
Increased detection of plasma lysophosphatidic acid (LPA) has been proposed as a potential diagnostic biomarker in ovarian cancer, but inconsistency exists in these reports. It has been shown that LPA can undergo an artificial increase during sample processing and analysis, which has not been accounted for in ovarian cancer research. The aim of this study is to provide a potential explanation about how the artificial increase in LPA may have interfered with previous LPA analysis in ovarian cancer research. Using an established LC-MS method, we measured LPA and other lysophospholipid levels in plasma obtained from three cohorts of patients: non-cancer controls, patients with benign ovarian tumors, and those with ovarian cancer. We did not find the LPA level to be higher in cancer samples. To understand this inconsistency, we observed that LPA content changed more significantly than other lysophospholipids as a function of plasma storage time while frozen. Additionally, only LPA was found to be adversely impacted by incubation time depending on the Ethylenediaminetetraacetic acid (EDTA) concentration used during blood drawing. We also show that the inhibition of autotaxin effectively prevented artificial LPA generation during incubation at room temperature. Our data suggests that the artificial changes in LPA content may contribute to the discrepancies reported in literature. Any future studies planning to measure plasma LPA should carefully design the study protocol to consider these confounding factors.

6 April 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
YOYu Okuma
Yu Okuma
LBLance B. Becker
Lance B. Becker
Kei HayashidaKei Hayashida
Kei Hayashida
TATomoaki Aoki
Tomoaki Aoki
KSKota Saeki
Kota Saeki
SKShinozaki Koichiro
Shinozaki Koichiro
Background: Cardiac arrest (CA) can induce oxidative stress after resuscitation, which causes cellular and organ damage. We hypothesized that post‐resuscitation normoxic therapy would protect organs against oxidative stress and improve oxygen metabolism and survival. We tested the oxygen‐sensitive reactive oxygen species from mitochondria to determine the association with hyperoxia‐induced oxidative stress. Methods and Results: Sprague–Dawley rats were subjected to 10‐minute asphyxia‐induced CA with a fraction of inspired O 2 of 0.3 or 1.0 (normoxia versus hyperoxia, respectively) after resuscitation. The survival rate at 48 hours was higher in the normoxia group than in the hyperoxia group (77% versus 28%, P <0.01), and normoxia gave a lower neurological deficit score (359±140 versus 452±85, P <0.05) and wet to dry weight ratio (4.6±0.4 versus 5.6±0.5, P <0.01). Oxidative stress was correlated with increased oxygen levels: normoxia resulted in a significant decrease in oxidative stress across multiple organs and lower oxygen consumption resulting in normalized respiratory quotient (0.81±0.05 versus 0.58±0.03, P <0.01). After CA, mitochondrial reactive oxygen species increased by ≈2‐fold under hyperoxia. Heme oxygenase expression was also oxygen‐sensitive, but it was paradoxically low in the lung after CA. In contrast, the HMGB‐1 (high mobility group box‐1) protein was not oxygen‐sensitive and was induced by CA. Conclusions: Post‐resuscitation normoxic therapy attenuated the oxidative stress in multiple organs and improved post‐CA organ injury, oxygen metabolism, and survival. Additionally, post‐CA hyperoxia increased the mitochondrial reactive oxygen species and activated the antioxidation system.

26 December 2019 in Cancers
Verified
Journal Article
Open access
PDF file
TYTsukasa Yagi
Tsukasa Yagi
CKCyrus Kuschner
Cyrus Kuschner
MSMuhammad Shoaib
Muhammad Shoaib
RCRishabh Choudhary
Rishabh Choudhary
LBLance Becker
Lance Becker
JKJunhwan Kim
Junhwan Kim
Ovarian cancer remains a highly lethal disease due to its late clinical presentation and lack of reliable early biomarkers. Protein-based diagnostic markers have presented limitations in identifying ovarian cancer. We tested the potential of phospholipids as markers of ovarian cancer by utilizing inter-related regulation of phospholipids, a unique property that allows the use of ratios between phospholipid species for quantitation. High-performance liquid chromatography mass spectrometry was used to measure phospholipid, lysophospholipid, and sphingophospholipid content in plasma from patients with benign ovarian masses, patients with ovarian cancer, and controls. We applied both absolute and relative phospholipid ratios for quantitation. Receiver operating characteristic analysis was performed to test the sensitivity and specificity. We found that utilization of ratios between phospholipid species greatly outperformed absolute quantitation in the identification of ovarian cancer. Of the phospholipids analyzed, species in phosphatidylcholine (PC), lysophosphatidylcholine (LPC), and sphingomyelin (SM) were found to have great biomarker potential. LPC(20:4)/LPC(18:0) carried the greatest capacity to differentiate cancer from control, SM(d18:1/24:1)/SM(d18:1/22:0) to differentiate benign from cancer, and PC(18:0/20:4)/PC(18:0/18:1) to differentiate benign from control. These results demonstrate the potential of plasma phospholipids as a novel marker of ovarian cancer by utilizing the unique characteristics of phospholipids to further enhance the diagnostic power.

10 October 2020 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MSMuhammad Shoaib
Muhammad Shoaib
LBLance Becker
Lance Becker

1 September 2021 in Mitochondrion
Verified
Journal Article
Closed access
CKCyrus E. Kuschner
Cyrus E. Kuschner
NKNancy Kim
Nancy Kim
MSMuhammad Shoaib
Muhammad Shoaib
RCRishabh C. Choudhary
Rishabh C. Choudhary
MNMitsuaki Nishikimi
Mitsuaki Nishikimi
JKJunhwan Kim
Junhwan Kim

30 April 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MNMitsuaki Nishikimi
Mitsuaki Nishikimi
KNKazuki Nishida
Kazuki Nishida
YSYuichiro Shindo
Yuichiro Shindo
MSMuhammad Shoaib
Muhammad Shoaib
DKDaisuke Kasugai
Daisuke Kasugai
NMNaoyuki Matsuda
Naoyuki Matsuda
A previous study has shown that late failure (> 48 hours) of high-flow nasal cannula (HFNC) was associated with intensive care unit (ICU) mortality. The aim of this study was to investigate whether failure of non-invasive respiratory support, including HFNC and non-invasive positive pressure ventilation (NPPV), was also associated with the risk of mortality even if it occurs in the earlier phase. We retrospectively analyzed 59 intubated patients for acute respiratory failure due to lung diseases between April 2014 and June 2018. We divided the patients into 2 groups according to the time from starting non-invasive ventilatory support until their intubation: ≤ 6 hours failure and > 6 hours failure group. We evaluated the differences in the ICU mortality between these two groups. The multivariate logistic regression analysis showed the highest mortality in the > 6 hours failure group as compared to the ≤ 6 hours failure group, with a statistically significant difference (p < 0.01). It was also associated with a statistically significant increased 30-day mortality and decreased ventilator weaning rate. The ICU mortality in patients with acute respiratory failure caused by lung diseases was increased if the time until failure of HFNC and NPPV was more than 6 hours.